Phaseline

Targets › NO

NO: drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 2; Cardiovascular; next expected readout May 2027.

Open in Phaseline: the race on NO, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of PennsylvaniaPotassium Nitrate
Nitric oxide donor; increases perfusion and fatty acid oxidation
NOPhase 2Heart Failure With Preserved Ejection FractionMay 2027

Conditions

Heart Failure With Preserved Ejection Fraction (3)

Modalities

small molecule (1)

Companies

University of Pennsylvania (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.